July 27, 2016 11:09 AM ET


Company Overview of Mimetogen Pharmaceuticals Inc.

Company Overview

Mimetogen Pharmaceuticals Inc., a biotechnology company, engages in designing and developing small molecule drugs to treat dry eye, glaucoma, age-related macular degeneration, keratoconus, and retinitis pigmentosa. The company’s products mimic the effects of neurotrophin proteins that help to maintain the health and growth of cells and tissues found in the eye. It provides tyrosine kinase agonists that prevent neuronal death; small molecule tyrosine kinase receptor agonists, which stimulates mucin secretion from conunctival goblet cells; and small molecule neurotrophin mimetics that rescues retinal pigment epithelial cells from oxidative stress-induced apoptosis. The company was founded in 2...

1000 de La Gauchetière Street West

Suite 900

Montreal, QC H3B 5H4


Founded in 2004





Key Executives for Mimetogen Pharmaceuticals Inc.

Chief Executive Officer, President and Director
Chief Financial Officer and Vice President of Finance
Chief Medical Officer
Senior Director - Drug Discovery
Senior Scientist - Medicinal Chemistry
Compensation as of Fiscal Year 2016.

Mimetogen Pharmaceuticals Inc. Key Developments

Allergan plc Enters into Licensing Agreement with Mimetogen Pharmaceuticals to Develop and Commercialize Tavilermide (MIM-D3) Topical Dry Eye Treatment

Allergan plc announced that its wholly owned subsidiary has entered into an exclusive licensing agreement with Mimetogen Pharmaceuticals to develop and commercialize tavilermide (MIM-D3), a topical formulation of a novel small molecule TrkA agonist for the treatment of dry eye disease. Under the terms of the agreement, Allergan will make an upfront payment of $50 million to Mimetogen and will fund phase 3 development of tavilermide. Mimetogen will additionally be entitled to receive potential milestone payments and royalties based on commercialization of the product. Tavilermide is a small cyclic peptidomimetic of NGF, a naturally occurring protein in the eye responsible for the maintenance of corneal nerves and epithelium. Tavilermide is differentiated from other investigational therapies in dry eye disease because it induces the production of mucin, a naturally occurring component of the tear film, and works upstream prior to inflammation.

Mimetogen Pharmaceuticals Inc. Announces Topline Results of its Second Clinical Study with MIM-D3 for the Treatment of Dry Eye Syndrome

Mimetogen Pharmaceuticals Inc. announced positive top line data from its second clinical study (Study Designation MIM-725) with MIM-D3, its lead drug for the treatment of dry eye syndrome. The trial demonstrated significant improvements in both signs and symptoms with 1% MIM-D3 versus placebo, together with excellent safety, comfort and tolerability profiles. Mimetogen has completed its initial analysis of the data and met with the FDA in order to confirm the outstanding requirements for the remainder of the clinical development plan. The 403-patient study (ClinicalTrials.gov Identifier: NCT01960010) utilized Ora's Controlled Adverse Environment (CAE(SM)) chamber to measure dry eye patients' ability to withstand a stressful drying environment on the eye, and patient diaries to measure the severity of their dry eye symptoms over the course of the study. In the study, MIM-D3 successfully demonstrated superiority over placebo in the pre-specified endpoints of both central and total corneal fluorescein staining (change from pre to post CAE) at week 8 (p = 0.0134 and p = 0.0500, respectively) as measured via the Ora Calibra(TM) Scale. MIM-D3 also significantly improved common vision-related function symptoms of dry eye disease as measured via the OSDI(R) questionnaire. The mean blurred vision, reading and watching TV scores were lower in the MIM-D3 group than in the respective placebo groups at week 8 (p = 0.0393, p = 0.0433 and p = 0.0046, respectively). MIM-D3 was comfortable, well tolerated and there were no unexpected or serious ocular adverse events. The most commonly reported ocular adverse events were reduction of visual acuity (MIM-D3, 3%; Placebo, 3%); instillation site pain (MIM-D3 1%; placebo, 1.5%) and eye irritation (MIM-D3, 0%; Placebo, 1.5%). All adverse ocular events were mild and transient in nature.

Similar Private Companies By Industry

Company Name Region
2007262 Ontario, Inc. Americas
2056273 Ontario, Inc. Americas
AB BioPharma Inc. Americas
AbCelex Technologies Inc. Americas
AbCellera Biologics Inc. Americas

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Mimetogen Pharmaceuticals Inc., please visit www.mimetogen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.